Literature DB >> 26785903

Usefulness of ketogenic diet in a girl with migrating partial seizures in infancy.

Tatsuo Mori1, Katsumi Imai2, Taikan Oboshi2, Yuh Fujiwara3, Saoko Takeshita3, Hirotomo Saitsu4, Naomichi Matsumoto4, Yukitoshi Takahashi2, Yushi Inoue2.   

Abstract

Migrating partial seizures in infancy (MPSI) are an age-specific epilepsy syndrome characterized by migrating focal seizures, which are intractable to various antiepileptic drugs and cause severe developmental delay. We report a case of MPSI with heterozygous missense mutation in KCNT1, which was successfully managed by ketogenic diet. At age 2months, the patient developed epilepsy initially manifesting focal seizures with eye deviation and apnea, then evolving to secondarily generalized clonic convulsion. Various antiepileptic drugs including phenytoin, valproic acid, zonisamide, clobazam, levetiracetam, vitamin B6, and carbamazepine were not effective, but high-dose phenobarbital allowed discontinuation of midazolam infusion. Ictal scalp electroencephalogram showed migrating focal seizures. MPSI was suspected and she was transferred to our hospital for further treatment. Potassium bromide (KBr) was partially effective, but the effect was transient. High-dose KBr caused severe adverse effects such as over-sedation and hypercapnia, with no further effects on the seizures. At age 9months, we started a ketogenic diet, which improved seizure frequency and severity without obvious adverse effects, allowing her to be discharged from hospital. Ketogenic diet should be tried in patients with MPSI unresponsive to antiepileptic drugs. In MPSI, the difference in treatment response in patients with and those without KCNT1 mutation remains unknown. Accumulation of case reports would contribute to establish effective treatment options for MPSI.
Copyright © 2016 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bromide; Ketogenic diet; Migrating partial seizures in infancy (MPSI); Potassium channel subfamily T member 1 (KCNT1)

Mesh:

Substances:

Year:  2016        PMID: 26785903     DOI: 10.1016/j.braindev.2015.12.012

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  3 in total

1.  Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy.

Authors:  Robertino Dilena; Jacopo C DiFrancesco; Maria Virginia Soldovieri; Antonella Giacobbe; Paolo Ambrosino; Ilaria Mosca; Maria Albina Galli; Sophie Guez; Monica Fumagalli; Francesco Miceli; Dario Cattaneo; Francesca Darra; Elena Gennaro; Federico Zara; Pasquale Striano; Barbara Castellotti; Cinzia Gellera; Costanza Varesio; Pierangelo Veggiotti; Maurizio Taglialatela
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

2.  The Efficacy of Ketogenic Diet for Specific Genetic Mutation in Developmental and Epileptic Encephalopathy.

Authors:  Ara Ko; Da E Jung; Se H Kim; Hoon-Chul Kang; Joon S Lee; Seung T Lee; Jong R Choi; Heung D Kim
Journal:  Front Neurol       Date:  2018-07-16       Impact factor: 4.003

3.  Epilepsy with migrating focal seizures: KCNT1 mutation hotspots and phenotype variability.

Authors:  Giulia Barcia; Nicole Chemaly; Mathieu Kuchenbuch; Monika Eisermann; Stéphanie Gobin-Limballe; Viorica Ciorna; Alfons Macaya; Laetitia Lambert; Fanny Dubois; Diane Doummar; Thierry Billette de Villemeur; Nathalie Villeneuve; Marie-Anne Barthez; Caroline Nava; Nathalie Boddaert; Anna Kaminska; Nadia Bahi-Buisson; Mathieu Milh; Stéphane Auvin; Jean-Paul Bonnefont; Rima Nabbout
Journal:  Neurol Genet       Date:  2019-10-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.